Hypertonic saline solution reduces the inflammatory response in endotoxemic rats

Imagem de Miniatura
Arquivos
art_THEOBALDO_Hypertonic_saline_solution_reduces_the_inflammatory_response_in_2012.PDF (336.74 KB)
Citações na Scopus
27
Tipo de produção
article
Data de publicação
2012
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
Citação
CLINICS, v.67, n.12, p.1463-1468, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: Volume replacement in septic patients improves hemodynamic stability. This effect can reduce the inflammatory response. The objective of this study was to evaluate the effect of 7.5% hypertonic saline solution versus 0.9% normal saline solution for volume replacement during an inflammatory response in endotoxemic rats. METHODS: We measured cytokines (serum and gut), nitrite, and lipid peroxidation (TBARS) as indicators of oxidative stress in the gut. Rats were divided into four groups: control group (C) that did not receive lipopolysaccharide; lipopolysaccharide injection without treatment (LPS); lipopolysaccharide injection with saline treatment (LPS + S); and lipopolysaccharide injection with hypertonic saline treatment (LPS + H). Serum and intestine were collected. Measurements were taken at 1.5, 8, and 24 h after lipopolysaccharide administration. RESULTS: Of the four groups, the LPS + H group had the highest survival rate. Hypertonic saline solution treatment led to lower levels of IL-6, IL-10, nitric oxide, and thiobarbituric acid reactive substances compared to 0.9% normal saline. In addition, hypertonic saline treatment resulted in a lower mortality compared to 0.9% normal saline treatment in endotoxemic rats. Volume replacement reduced levels of inflammatory mediators in the plasma and gut. CONCLUSION: Hypertonic saline treatment reduced mortality and lowered levels of inflammatory mediators in endotoxemic rats. Hypertonic saline also has the advantage of requiring less volume replacement.
Palavras-chave
LPS, Hypertonic Solution, Interleukin, Oxidative Stress, Intestine
URI
https://observatorio.fm.usp.br/handle/OPI/430
Referências
  1. Angle N, 2000, SHOCK, V14, P503, DOI 10.1097/00024382-200014050-00002
  2. Barbeiro DF, 2011, IMMUNOBIOLOGY, V216, P302, DOI 10.1016/j.imbio.2010.08.002
  3. BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290
  4. Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
  5. Ci XX, 2010, INFLAMMATION, V33, P126, DOI 10.1007/s10753-009-9166-7
  6. Ciesla DJ, 2000, SHOCK, V14, P265, DOI 10.1097/00024382-200014030-00004
  7. Ciesla DJ, 2000, SHOCK, V14, P9
  8. Ciesla DJ, 2001, J TRAUMA, V50, P206, DOI 10.1097/00005373-200102000-00004
  9. Dal-Pizzol F, 2006, AM J RESP CRIT CARE, V173, P84, DOI 10.1164/rccm.200507-1118OC
  10. FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
  11. Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354
  12. Lenassi Metka, 2007, Saline Systems, V3, P3, DOI 10.1186/1746-1448-3-3
  13. Machado MCC, 2006, PANCREAS, V32, P80, DOI 10.1097/01.mpa.0000191645.01926.8f
  14. Melo ES, 2010, MOL IMMUNOL, V47, P2587, DOI 10.1016/j.molimm.2010.06.011
  15. Melo ES, 2010, IMMUNOBIOLOGY, V215, P435, DOI 10.1016/j.imbio.2009.09.002
  16. Moretti AIS, 2009, PANCREAS, V38, P507, DOI 10.1097/MPA.0b013e31819fef75
  17. Oberbeck R, 2001, CRIT CARE MED, V29, P380, DOI 10.1097/00003246-200102000-00029
  18. Oreopoulos GD, 2000, SHOCK, V14, P414
  19. Oreopoulos GD, 2000, SHOCK, V14, P409, DOI 10.1097/00024382-200014030-00029
  20. Rios ECS, 2011, CLINICS, V66, P469, DOI 10.1590/S1807-59322011000300019
  21. Rios ECS, 2010, CLIN EXP PHARMACOL P, V37, P35, DOI 10.1111/j.1440-1681.2009.05220.x
  22. Rizoli SB, 2000, AM J PHYSIOL-CELL PH, V279, pC619
  23. Song GY, 1999, SURGERY, V126, P378, DOI 10.1016/S0039-6060(99)70180-7
  24. Soriano FG, 2006, CRIT CARE MED, V34, P1073, DOI 10.1097/01.CCM.0000206470.47721.8D
  25. Soriano FG, 2011, SHOCK, V35, P560, DOI 10.1097/SHK.0b013e31820fe5d5
  26. Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008
  27. Steinhauser ME, 1999, J IMMUNOL, V162, P392
  28. Texereau J, 2004, CRIT CARE MED, V32, pS313, DOI 10.1097/01.CMM.0000126363.46191.DC
  29. Thiel M, 2001, J LEUKOCYTE BIOL, V70, P261
  30. van Haren FMP, 2012, SHOCK, V37, P268, DOI 10.1097/SHK.0b013e31823f152f
  31. Zallen G, 2000, J TRAUMA, V48, P45, DOI 10.1097/00005373-200001000-00008

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/51